Edwards Lifesciences (EW) Depreciation & Amortization (CF) (2009 - 2026)

Edwards Lifesciences' Depreciation & Amortization (CF) history runs 18 years deep, the most recent figure standing at $40.9 million for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) rose 11.75% year-over-year to $40.9 million; the TTM figure through Mar 2026 stood at $160.9 million (up 4.96% YoY), while the FY2025 annual figure was $156.6 million, up 0.9% from the prior year.
• Depreciation & Amortization (CF) was $40.9 million for Q1 2026 at Edwards Lifesciences, down from $42.7 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $42.7 million in Q4 2025 to a low of $34.1 million in Q2 2022.
• Historically, Depreciation & Amortization (CF) has averaged $37.5 million across 5 years, with a median of $36.7 million in 2023.
• Biggest YoY gain for Depreciation & Amortization (CF) was 16.08% in 2024; the steepest drop was 6.5% in 2024.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $35.4 million in 2022, then rose by 3.67% to $36.7 million in 2023, then climbed by 16.08% to $42.6 million in 2024, then grew by 0.23% to $42.7 million in 2025, then decreased by 4.22% to $40.9 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $40.9 million (Q1 2026), $42.7 million (Q4 2025), and $39.2 million (Q3 2025), per Business Quant data.